Immunology Investor Event

Our key growth drivers DupixentⓇ €13bn+ COPD not included¹ Vaccines >2x sales by the end of the decade² Pipeline >90 projects Majority in Immunology, Oncology, Neurology, and Vaccines 1. €13bn+ refers to the peak sales ambition, not including COPD 2. vs. 2018, risk-adjusted, internal estimate, excluding Covid-19 vaccine DupixentⓇ is jointly developed and co-commercialized with Regeneron 6 Immunology Investor Event sanofi

View entire presentation